IMCR
Immunocore Holdings PLC - ADR

511
Mkt Cap
$1.95B
Volume
785,566.00
52W High
$39.33
52W Low
$23.15
PE Ratio
-66.16
IMCR Fundamentals
Price
$39.01
Prev Close
$38.65
Open
$39.13
50D MA
$34.00
Beta
0.77
Avg. Volume
318,620.74
EPS (Annual)
-$1.02
P/B
4.95
Rev/Employee
$629,477.75
Loading...
Loading...
News
all
press releases
Fiera Capital Corp Purchases 7,924 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR
Fiera Capital Corp lifted its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 1.0% in the second quarter, according to the company in its most recent disclosure with...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Fox Run Management L.L.C. Invests $372,000 in Immunocore Holdings PLC Sponsored ADR $IMCR
Fox Run Management L.L.C. purchased a new stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund...
MarketBeat·6d ago
News Placeholder
Immunocore (NASDAQ:IMCR) Price Target Raised to $36.00 at Morgan Stanley
Morgan Stanley upped their price target on shares of Immunocore from $34.00 to $36.00 and gave the stock an "equal weight" rating in a research report on Monday...
MarketBeat·9d ago
News Placeholder
Immunocore (NASDAQ:IMCR) Announces Earnings Results
Immunocore (NASDAQ:IMCR - Get Free Report) issued its quarterly earnings data on Thursday. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.30) by...
MarketBeat·11d ago
News Placeholder
Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Immunocore (IMCR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·14d ago
News Placeholder
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
Zacks·17d ago
News Placeholder
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
Zacks·3mo ago
News Placeholder
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.
Zacks·3mo ago
News Placeholder
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Zacks·3mo ago
News Placeholder
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
Zacks·3mo ago

Latest IMCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.